

Jiro Nakamura M.D., Ph.D. Joins NeuroMetrix Scientific Advisory Board

WALTHAM, Mass.--(BUSINESS WIRE)-- [NeuroMetrix, Inc.](#) (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Jiro Nakamura, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Nakamura is Professor, Division of Diabetes, Department of Internal Medicine, Diabetes Center at the Aichi Medical University School of Medicine in Nagakute, Japan.

Dr. Nakamura has focused on diabetes throughout his career. His particular emphasis has been on the vascular and cardiovascular complications of diabetes as well as on diabetic neuropathy. Dr. Nakamura has published widely, been the Principal Investigator on a range of clinical studies, and serves on the editorial boards of the Journal of Diabetes Investigation, Diabetology International, and Experimental Diabetes Research. He is a Member of the American Diabetes Association, International Diabetes Federation, Japan Diabetes Society and other professional societies, often serving as a Board Member or Member of the Scientific Committee. Dr. Nakamura is considered a leader in the field of diabetes research and treatment.

"We are honored that Dr. Nakamura has joined our Scientific Advisory Board," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. "This eminent group of international leaders in the detection, management and treatment of the neurological complications of diabetes plays a key role in our product development efforts. Dr. Nakamura's position in the Japan medical profession and understanding of local medical practice will be a valuable near-term source of advice and guidance as we move toward the launch of NC-stat DPNCheck in the Japanese market during 2014."

Dr. Nakamura will join the following members of the NeuroMetrix Scientific Board:

David. G. Armstrong, D.P.M., M.D., Ph.D. - Professor of Surgery at the University of Arizona and co-founder of the Southern Arizona Limb Salvage Alliance (SALSA).

Andrew J.M. Boulton, M.R.C.P.(UK), M.D., F.R.C.P - Professor of Medicine at the University of Manchester and Consulting Physician, Manchester Royal Infirmary, Manchester, U.K. and Professor of Medicine, Diabetes Research Institute, University of Miami.

Bruce A. Perkins, M.D., M.P.H., F.R.C.P. (C) - Assistant Professor at the University of Toronto, Canada.

Soloman Tesfaye, M.B., Ch.B., M.D., F.R.C.P., (UK) - Consultant Physician/Endocrinologist at the Royal Hallamshire Hospital, Sheffield, U.K. and Honorary Professor of Diabetic Medicine at the University of Sheffield.

Aaron I. Vinik, M.D., Ph.D., F.C.P., F.A.C.P. (FRCP) - Professor of Medicine, Pathology and Neurobiology and Director of Research at the Neuroendocrine Unit of the Strelitz Diabetes Center for Endocrine and Metabolic Disorders, Eastern Virginia Medical School, Norfolk, Virginia.

Dan Ziegler, M.D., F.R.C.P.E - Professor of Medicine at the Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, and the Department of Metabolic Diseases, University Hospital, Dusseldorf, Germany.

About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at \$14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy.

The company also markets the DPNCheck® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit <http://www.neurometrix.com>.

Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media